Iwakiri, Katsuhiko
Fujiwara, Yasuhiro
Manabe, Noriaki
Ihara, Eikichi
Kuribayashi, Shiko
Akiyama, Junichi
Kondo, Takashi
Yamashita, Hiroshi
Ishimura, Norihisa
Kitasako, Yuichi
Iijima, Katsunori
Koike, Tomoyuki
Omura, Nobuo
Nomura, Tsutomu
Kawamura, Osamu
Ohara, Shuichi
Ozawa, Soji
Kinoshita, Yoshikazu
Mochida, Satoshi
Enomoto, Nobuyuki
Shimosegawa, Tooru
Koike, Kazuhiko
Article History
Received: 3 February 2022
Accepted: 3 February 2022
First Online: 28 February 2022
Declarations
:
: Any financial relationship with enterprises, businesses or academic institutions in the subject matter or materials discussed in the manuscript are as follows: (1) those from which the authors, the spouse, partner or immediate relatives of the authors have received individually any income, honoraria or any other type of renumeration; Astellas Pharma, AstraZeneca, Otsuka Pharmaceutical, Daiichi Sankyo, Takeda Pharmaceutical, Mochida Pharmaceutical, Tsumura & CO., EA Pharma, Mylan EPD, and (2) those from which the authors have received research grant: Fujifilm, Taiho Pharmaceutical, Tsumura & CO, Bristol-Myers Squibb, and (3) those from which the authors have received scholarship; Astellas Pharma, AbbVie, EA Pharma, Eisai, MSD, Ono Pharmaceutical, Covidien Japan, Taiho Pharmaceutical, Takeda Pharmaceutical, Chugai Pharmaceutical, Novartis Pharma, Bayer Yakuhin, Asahi Kasei Pharma, Nippon Kayaku, Mochida Pharmaceutical, Zeria Pharmaceutical, Daiichi Sankyo, Otsuka Pharmaceutical, and (4) those from which the authors have received individually endowed chair; Ohga Pharmacy, Otsuka Pharmaceutical, Ono Pharmaceutical, Sanwa Kagaku Kenkyusho, Terumo, FANCL, Fujifilm Medical, Miyarisan Pharmaceutical, and (5) those from which the authors have received individually contribution; EA Pharma, Otsuka Pharmaceutical, Daiichi Sankyo, Takeda Pharmaceutical.